This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past. CNTX-3001 is a novel, non-opioid small molecule
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
16
non-opioid analgesic
Placebo product
Neurovations
Napa, California, United States
Incidence of treatment emergent adverse events
Number of participants with TEAEs, which includes laboratory test variables
Time frame: From baseline to the end of treatment visit (Day 7)
Maximum Observed Plasma Concentration (Cmax) of CNTX-3001
Time frame: Pre dose to up to 4 hours post dose
Time to Maximum Observed Plasma Concentration (Tmax) of CNTX-3001
Time frame: Pre dose to up to 4 hours post dose
Area Under the Concentration-time Curve up to the Last Measurable Concentration of CNTX-3001
Time frame: Pre dose to up to 4 hours post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.